A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Part of paid clinical trials in Palo Alto, California.

Sponsor
Immunome, Inc.
Study ID
NCT07505771
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 177Lu-IM-3050 — DRUG
    177Lu-IM-3050 is a FAP-directed radiopharmaceutical

Study Details

IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.

Key Dates

First listed
Apr 1, 2026
Start date
Jun 19, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2034

Study Design

Enrollment
105 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation: 177Lu-IM-3050
    177Lu-IM-3050 administered intravenously on a 6-week cycle
  • Experimental: Dose Expansion: 177Lu-IM-3050
    177Lu-IM-3050 administered intravenously on a 6-week cycle

Primary Outcome Measure

Safety and tolerability of 177Lu-IM-3050 in participants with advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs) [ Time Frame: From first dose of 177Lu-IM-3050 through at least 42 days following last dose of study treatment serious; up to approximately 5 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicinePalo AltoCalifornia94305-
Excel Diagnostics and Nuclear Oncology CenterHoustonTexas77042-
University of Texas - MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Palo Alto, CA

By research site
Stanford University School of Medicine· Palo Alto, CAExcel Diagnostics and Nuclear Oncology Center· Houston, TXUniversity of Texas - MD Anderson Cancer Center· Houston, TX

Related Studies